Re-Vana Therapeutics
Latest round
- Series A
Last raised
- Nov 2022
Total raised
- $5.5M
Investors
- 5
About Re-Vana Therapeutics
Founded in 2015 and headquartered in Belfast, UK, Re-Vana Therapeutics Ltd. focuses on developing advanced ocular drug delivery solutions. The founders, David Jones and Raghu Thakur, established the company to improve the management of sight-threatening diseases.Re-Vana Therapeutics specializes in innovative ocular delivery systems, focusing on biodegradable implants designed for sustained release of therapeutics. Their core products, EyeLief® and OcuLief®, utilize patented technology to facilitate the controlled intraocular release of Active Pharmaceutical Ingredients (APIs) over extended periods, addressing the needs of patients suffering from sight-threatening diseases. EyeLief® is a pre-formed, photo-crosslinked biodegradable implant that provides sustained release for up to six months at adjustable rates, making it suitable for small, potent molecules. OcuLief®, on the other hand, is an injectable gel that forms a crosslinked implant in situ, allowing for higher release rates of biologics over six to twelve months.The revenue model for Re-Vana Therapeutics is primarily driven by strategic partnerships with leading pharmaceutical companies, focusing on the development and commercialization of their innovative ocular delivery technologies. The company engages in B2B transactions, collaborating with pharmaceutical partners to conduct preformulation and preclinical feasibility studies that lead to the integration of Re-Vana’s technologies into existing treatment frameworks. Revenue generation may stem from licensing agreements where pharmaceutical firms pay to utilize Re-Vana's patented technologies, potentially structured as upfront fees followed by milestone payments tied to regulatory progress and commercial success.In November 2022, Re-Vana Therapeutics Ltd. Re-Vana aims to introduce new products into the market and expand its geographic footprint, targeting additional regions in Europe and Asia by 2024.
Who invested in Re-Vana Therapeutics
5 investors across 1 round
See all investors in Re-Vana Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 28, 2022
Amount
$5.5M
Investors
Questions about Re-Vana Therapeutics
Who invested in Re-Vana Therapeutics?
Re-Vana Therapeutics has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Re-Vana Therapeutics raised?
Re-Vana Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Re-Vana Therapeutics last raise money?
Re-Vana Therapeutics's most recent round on record is a Series A, in Nov 2022.
What does Re-Vana Therapeutics do?
Founded in 2015 and headquartered in Belfast, UK, Re-Vana Therapeutics Ltd.
Where is Re-Vana Therapeutics headquartered?
Re-Vana Therapeutics is headquartered in Belfast, UK.
Which VCs invest in companies like Re-Vana Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back healthcare specialists companies at Re-Vana Therapeutics's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series A
Raising like Re-Vana Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.